ERBB2 and breast carcinoma: More importantly, our results showed that the miR-497/FGF-23 axis had a better influence on responding to the cardiotoxicity of trastuzumab, which was stronger than miR-497 and FGF-23 alone in HER2-positive breast cancer patients.